Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | PPARA | Q07869 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | FBP1 | P09467 | 8/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7984260 | 0.88 | TSHR (0.64) | TSHRPPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL3585865 | 0.87 | FBP1 (0.60) | TSHRPPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL7980993 | 0.86 | FBP1 (0.60) | TSHRPPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL16585371 | 0.86 | FBP1 (0.59) | TSHRPPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL1116734 | 0.86 | CYP1A2 (0.61) | TSHRPPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL2824290 | 0.86 | PPARA (0.61) | TSHRPPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL24177870 | 0.85 | PPARA (0.59) | TSHRPPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL4678053 | 0.85 | FBP1 (0.58) | TSHRPPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL3905158 | 0.85 | PPARA (0.59) | TSHRPPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL4682766 | 0.83 | FBP1 (0.69) | TSHRPPARAABCB11CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-8906945-B2 | Inhibitors of bacterial type III secretion system | MICROBIOTIX, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
| EP-2416661-A1 | INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM | Microbiotix, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010118046-A1 | INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM | MICROBIOTIX, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118046-A1 | INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM | MICROBIOTIX, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-4304907-A | Bicyclo lactone intermediates for prostaglandin analogs | THE UPJOHN COMPANY (US) | 1981-12-08 | — | — | US | disclosed |
| US-4303796-A | 16-Phenoxy prostaglandin F2α analogs | THE UPJOHN COMPANY (US) | 1981-12-01 | — | — | US | disclosed |
| US-4116988-A | 16-Phenoxy prostaglandin E1 analogs | THE UPJOHN COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
| US-4116989-A | 16-Phenoxy prostaglandin F1α analogs | THE UPJOHN COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
| US-4087616-A | 16-Phenoxy prostaglandin A2 analogs | THE UPJOHN COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-3931279-A | 5-Oxa prostaglandin F2.sub.α analogs | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | TSHR 914/4885PPARA 1848/4885ABCB11 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.